Oncotelic Therapeutics
OTC: OTLCAgoura Hills, US · Delaware corporation
Oncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
Founders & leadership
AM
ANTHONY MAIDAinExecutive
SA
SHAH AMITExecutive
SF
SEYMOUR FEINExecutive
SS
SARAN SAUNDinExecutive
MM
Matthew M. LoarExecutive
VT
Vuong TrieuCEO & Chairman
VT
VUONG TRIEUNamed on SEC filing
WD
William D. SchwietermanNamed on SEC filing
DR
Donald R. ReynoldsNamed on SEC filing
SC
Simon C. PedderNamed on SEC filing
BW
Bobby W. Sandage, Jr.Named on SEC filing
DJ
David J. ChaplinNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$33.5M disclosed across 6 of 7 rounds · 2018–2026
▶$711.8KraisedJul 2026 · 33 investors · BiotechnologyRule 506(b)
▶$711.8KraisedJul 2026 · 33 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VUONG TRIEUExecutive Officer, Director
- STEVEN KINGDirector
- ANTHONY MAIDAExecutive Officer, Director
- SHAH AMITExecutive Officer
- SEYMOUR FEINExecutive Officer
- SARAN SAUNDExecutive Officer
- Offering amount
- $711.8K
- Amount sold
- $711.8K
- Placement agents
- N.A.
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$275KraisedDec 2025 · 4 investors · BiotechnologyRule 506(b)
▶$275KraisedDec 2025 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- VUONG TRIEUExecutive Officer, Director
- Offering amount
- $12.5M
- Amount sold
- $275K
- Minimum investment
- $25K
- Sales commissions
- $1.9M
- Proceeds to insiders
- $10.6M
- Placement agents
- J.H. DARBIE & CO
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5MofferedJul 2023 · 15 investors · BiotechnologyRule 506(b)
▶$5MofferedJul 2023 · 15 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vuong TrieuExecutive Officer, Director
- Saran SaundExecutive Officer
- Seymour FeinExecutive Officer
- Anthony MaidaExecutive Officer
- Amit ShahExecutive Officer
- Offering amount
- $5M
- Minimum investment
- $25K
- Sales commissions
- $650K
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedAug 2020 · 24 investors · BiotechnologyRule 506(b)
▶$2MraisedAug 2020 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Vuong TrieuExecutive Officer, Director
- Amit ShahExecutive Officer
- Chuho ParkExecutive Officer
- Offering amount
- $5M
- Amount sold
- $2M
- Minimum investment
- $50K
- Sales commissions
- $256K
- First sale
- Jul 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$600KraisedMay 2019 · 4 investors · BiotechnologyRule 506(b)
▶$600KraisedMay 2019 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fatih UckunExecutive Officer
- Chulho ParkExecutive Officer
- Matthew LoarExecutive Officer
- William SchwietermanDirector
- Vuong TrieuExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $600K
- Minimum investment
- $38K
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$27MraisedMay 2019 · 26 investors · BiotechnologyRule 506(b)
▶$27MraisedMay 2019 · 26 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Fatih UckunExecutive Officer
- Matthew LoarExecutive Officer
- Vuong TrieuExecutive Officer, Director
- Chulho ParkExecutive Officer
- William SchwietermanDirector
- Offering amount
- $27M
- Amount sold
- $27M
- Sales commissions
- $545K
- Placement agents
- Stout Risius Ross Advisors, LLC
- First sale
- Apr 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.9MraisedApr 2018 · 38 investors · BiotechnologyRule 506(b)
▶$2.9MraisedApr 2018 · 38 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- William D. SchwietermanExecutive Officer, Director
- Matthew M. LoarExecutive Officer
- Donald R. ReynoldsDirector
- Simon C. PedderDirector
- Bobby W. Sandage, Jr.Director
- David J. ChaplinExecutive Officer, Director
- Offering amount
- $12M
- Amount sold
- $2.9M
- Minimum investment
- $25K
- Sales commissions
- $400K
- Placement agents
- Divine Capital Markets LLC
- First sale
- Apr 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 1
by search overlap
Companies competing with Oncotelic Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present at OTCQB Virtual Investor Conference - InvestorWire (IW)investorwire.com · Aug 2026InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Brings AI and Robotics Together in New Platform - InvestorWire (IW)investorwire.com · Jul 2026
Oncotelic Therapeutics (OTLC) grants 1,500 performance RSUs to directorstocktitan.net · Jul 2026Frequently asked questions
- What does Oncotelic Therapeutics do?
- Oncotelic is a biopharmaceutical company developing oncology therapeutics, including immuno-oncology and nanomedicine approaches, and applying AI technology to drug development. It focuses on cancer treatments and other therapeutic areas.
- How much funding has Oncotelic Therapeutics raised?
- Oncotelic Therapeutics has disclosed $33.5M raised across 6 of its 7 known rounds.
- Where is Oncotelic Therapeutics headquartered?
- Oncotelic Therapeutics is headquartered in Agoura Hills, US.